FDA approves Juvmo (tavapadon), a selective D1/D5 receptor partial agonist, for Parkinson disease based on phase 3 TEMPO trial data.

Time-restricted eating may be a safe and reasonable method for improving disease markers in people with Huntington disease.

An FDA panel supports Galleri, a blood test designed to detect multiple cancer types, despite some concern that the test is not reliable.

Multiple-component and multifactorial interventions do not meaningfully improve fall rates among older people compared with usual care.

Pediatric patients receiving GLP-1 receptor agonist treatment appear to have higher rates of nutritional deficiency.

Patients with atypical Alzheimer disease frequently fail to meet the clinical criteria required to receive targeted anti-amyloid therapies.

Treatment with intravenous inebilizumab is associated with a significantly decreased risk for exacerbations in adults with generalized myasthenia gravis.

Assessment tools significantly influence the reported global prevalence of cognitive frailty among older adult populations.

Initiating hormone replacement therapy near the onset of menopause may reduce the risk for LATE neuropathological changes in older women.

Continuous activity monitoring with wearable devices reveals that daily step count patterns correlate with disability severity in progressive MS.

A novel speech-based model successfully distinguishes between nonfluent, logopenic, and semantic variants of primary progressive aphasia.

Women with cerebral palsy appear to receive significantly less preventive gynecologic care vs women that do not have cerebral palsy.